Stock CAMX CAMURUS AB
Add to a list
To use this feature you must be a member
Log inSign up

Company Camurus AB

Equities

CAMX

SE0007692850

Pharmaceuticals

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
615.5 SEK +3.19% Intraday chart for Camurus AB +3.62% +14.41%
Jun. 25 Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study CI
May. 23 Camurus' Rare Growth Disorder Drug Accepted for Review in EU MT

Business Summary

Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.

Number of employees: 218

Sales per Business

SEK in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
956 100.0 % 1,717 100.0 % +79.52%

Sales per region

SEK in Million2022Weight2023Weight Delta
Australia
26.3 %
355 37.1 % 451 26.3 % +27.09%
United States
24.2 %
20 2.1 % 415 24.2 % +2,014.70%
United Kingdom
18.1 %
-- 311 18.1 % -
Finland
11.2 %
-- 193 11.2 % -
Europe
8.9 %
477 49.9 % 153 8.9 % -68.02%
Norway
4.9 %
-- 85 4.9 % -
Sweden
4.6 %
68 7.1 % 79 4.6 % +16.43%
Asia
1.8 %
-- 30 1.8 % -
North America
0.0 %
-- 1 0.0 % -

Managers

Managers TitleAgeSince
Sven Fredrik Tiberg CEO
 Chief Executive Officer 61 01-12-31
Jon Alonso DFI
 Director of Finance/CFO 51 22-01-31
Alberto Pedroncelli CTO
 Chief Tech/Sci/R&D Officer - 23-05-31
Torsten Malmström CTO
 Chief Tech/Sci/R&D Officer 56 12-12-31
Markus Johnsson CTO
 Chief Tech/Sci/R&D Officer 52 20-12-31
Agneta Svedberg CTO
 Chief Tech/Sci/R&D Officer 61 14-12-31
Fredrik Joabsson IRC
 Investor Relations Contact 52 00-12-31
Lisa Albertsson AUD
 Comptroller/Controller/Auditor - 23-05-09
Annette Mattsson LAW
 General Counsel 58 16-12-31
Richard Jameson PRN
 Corporate Officer/Principal 60 16-05-31

Members of the board

Members of the board TitleAgeSince
Folke Per-Olof Wallström CHM
 Chairman 75 09-12-31
Sven Fredrik Tiberg CEO
 Chief Executive Officer 61 01-12-31
Stig Anders Lindberg BRD
 Director/Board Member 52 20-12-31
Erika Johanna Söderberg Johnson BRD
 Director/Board Member 54 23-05-09
Hege Hellstrom BRD
 Director/Board Member 59 20-05-06
Stefan K. Persson BRD
 Director/Board Member 57 22-05-11

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 57,623,618 32,060,297 ( 55.64 %) 0 55.64 %

Shareholders

NameEquities%Valuation
Per Gunnar Sandberg
35.04 %
20,530,692 35.04 % 1 163 M kr
Fjärde AP-fonden
4.455 %
2,610,766 4.455 % 148 M kr
Sven Fredrik Tiberg
2.756 %
1,615,000 2.756 % 91 M kr
Lancelot Asset Management AB
1.067 %
625,000 1.067 % 35 M kr
AFA Sjukförsäkringsaktiebolag (Invt Mgmt)
1.048 %
614,293 1.048 % 35 M kr
Devon Equity Management Ltd.
1.009 %
591,475 1.009 % 34 M kr
Svenskt Näringsliv
0.8532 %
500,000 0.8532 % 28 M kr
Camurus Lipid Research Foundation
0.8299 %
486,350 0.8299 % 28 M kr
Didner & Gerge Fonder AB
0.7312 %
428,504 0.7312 % 24 M kr
Länsförsäkringar Fondförvaltning AB
0.6569 %
384,921 0.6569 % 22 M kr

Company contact information

Camurus AB

Ideon Science Park

223 70, Lund

+46 4 62 86 57 30

http://www.camurus.com
address Camurus AB(CAMX)

Group companies

NameCategory and Sector
Camurus Development AB

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Camurus AB

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
615.5 SEK
Average target price
621.5 SEK
Spread / Average Target
+0.97%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CAMURUS AB Stock Camurus AB
+14.41% 3.42B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+57.48% 827B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.18% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.37% 319B
ABBVIE INC. Stock AbbVie Inc.
+7.45% 294B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.62% 240B
NOVARTIS AG Stock Novartis AG
+14.55% 221B
ROCHE HOLDING AG Stock Roche Holding AG
-0.33% 219B
AMGEN INC. Stock Amgen Inc.
+8.14% 167B
PFIZER, INC. Stock Pfizer, Inc.
-2.99% 158B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CAMX Stock
  4. Company Camurus AB